Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 1
2007 4
2008 3
2009 1
2010 3
2011 3
2012 1
2013 3
2014 1
2015 2
2016 1
2017 1
2018 3
2019 3
2020 2
2021 4
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.
Plaks V, Rossi JM, Chou J, Wang L, Poddar S, Han G, Wang Z, Kuang SQ, Chu F, Davis RE, Vega F, Bashir Z, Jacobson CA, Locke FL, Reagan PM, Rodig SJ, Lekakis LJ, Flinn IW, Miklos DB, Bot A, Neelapu SS. Plaks V, et al. Blood. 2021 Sep 23;138(12):1081-1085. doi: 10.1182/blood.2021010930. Blood. 2021. PMID: 34041526 Free PMC article. Clinical Trial. No abstract available.
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Jacobson CA, et al. Among authors: plaks v. Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8. Lancet Oncol. 2022. PMID: 34895487 Clinical Trial.
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, Thieblemont C, Wermke M, Song KW, Avivi I, Kuruvilla J, Dührsen U, Zheng Y, Vardhanabhuti S, Dong J, Bot A, Rossi JM, Plaks V, Sherman M, Kim JJ, Kerber A, Kersten MJ. Topp MS, et al. Among authors: plaks v. Br J Haematol. 2021 Nov;195(3):388-398. doi: 10.1111/bjh.17673. Epub 2021 Sep 29. Br J Haematol. 2021. PMID: 34590303 Clinical Trial.
Enrichment of circulating tumor-derived extracellular vesicles from human plasma.
Yoh KE, Lowe CJ, Mahajan S, Suttmann R, Nguy T, Reichelt M, Yang J, Melendez R, Li Y, Molinero L, Ruppel J, Xu W, Plaks V. Yoh KE, et al. Among authors: plaks v. J Immunol Methods. 2021 Mar;490:112936. doi: 10.1016/j.jim.2020.112936. Epub 2020 Nov 24. J Immunol Methods. 2021. PMID: 33242493
New Horizons in Advocacy Engaged Physical Sciences and Oncology Research.
Samson S, Northey JJ, Plaks V, Baas C, Dean I, LaBarge MA, Goga A, Van't Veer LJ, Weaver VM. Samson S, et al. Among authors: plaks v. Trends Cancer. 2018 Apr;4(4):260-264. doi: 10.1016/j.trecan.2018.02.002. Epub 2018 Mar 15. Trends Cancer. 2018. PMID: 29606307 Free PMC article. Review.
Ferritin nanoparticles as magnetic resonance reporter gene.
Cohen B, Ziv K, Plaks V, Harmelin A, Neeman M. Cohen B, et al. Among authors: plaks v. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Mar-Apr;1(2):181-8. doi: 10.1002/wnan.11. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009. PMID: 20049789 Review.
Cancer. Circulating tumor cells.
Plaks V, Koopman CD, Werb Z. Plaks V, et al. Science. 2013 Sep 13;341(6151):1186-8. doi: 10.1126/science.1235226. Science. 2013. PMID: 24031008 Free PMC article.
34 results